DARA Biosciences (DARA) and Check Cap (CHEK) Financial Comparison

DARA Biosciences (NASDAQ: DARA) and Check Cap (NASDAQ:CHEK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, institutional ownership, dividends, valuation and risk.

Profitability

This table compares DARA Biosciences and Check Cap’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DARA Biosciences -228.42% -145.61% -100.38%
Check Cap N/A -129.20% -100.81%

Risk and Volatility

DARA Biosciences has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, Check Cap has a beta of -0.68, meaning that its stock price is 168% less volatile than the S&P 500.

Valuation & Earnings

This table compares DARA Biosciences and Check Cap’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
DARA Biosciences N/A N/A N/A ($0.52) -1.69
Check Cap N/A N/A -$8.82 million ($0.61) -1.60

DARA Biosciences is trading at a lower price-to-earnings ratio than Check Cap, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

19.0% of Check Cap shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for DARA Biosciences and Check Cap, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DARA Biosciences 0 0 0 0 N/A
Check Cap 0 0 3 0 3.00

Check Cap has a consensus target price of $5.67, suggesting a potential upside of 480.48%. Given Check Cap’s higher probable upside, analysts plainly believe Check Cap is more favorable than DARA Biosciences.

Summary

Check Cap beats DARA Biosciences on 6 of the 9 factors compared between the two stocks.

DARA Biosciences Company Profile

DARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company’s primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.

Check Cap Company Profile

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing. The Company’s scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. Its scanning capsule employs low-dose X-rays, which allow the system to image the interior lining of the colon even when surrounded by intestinal content. Its capsule transmits information to a receiving device worn on the patient’s body that stores the information for off-line analysis.

Receive News & Ratings for DARA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DARA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply